WÖRWAG Pharma

What WÖRWAG Pharma does

Wörwag Pharma is a family-owned German pharmaceutical company founded in 1971 by Dr. Fritz Wörwag and headquartered in Böblingen. It specializes in biofactor-based medicines - formulations of vitamins, minerals, trace elements, and herbal ingredients - organized around four therapeutic areas: diabetic comorbidities (including diabetic polyneuropathy and fatty liver disease), nervous system disorders, musculoskeletal health, and immune system support. The portfolio spans prescription (Rx) and over-the-counter (OTC) products plus dietary supplements, with flagship brands Milgamma and Magnerot joined by newer offerings benfotiamine-derived regimens, ReDia® (fiber-based metabolic health, EU-patent protected), and Lagosa Triplex® (omega-3/choline/milk thistle combination launched May 2026). The company employs 1,500+ people across more than 25 nationalities and operates in 35+ countries spanning Europe, Asia, and South America through wholly-owned country subsidiaries.

The business model is built on a pharmacy-exclusive distribution model. Products reach consumers and patients only through licensed pharmacies, generating revenue through one-time product sales at region-specific OTC and Rx price points. Distribution is supported by an enterprise field sales motion targeting physicians and pharmacists, complemented by medical education and a global Health Academy webinar series. Manufacturing was historically outsourced but has been progressively internalized via two acquisitions: Wörwag Pharma Operations (WPO) in Łódź, Poland, acquired in 2021, and Wörwag Pharma Production (WPP, formerly Mauermann Arzneimittel) in Pöcking, Bavaria, acquired in late 2023. The company remains under Wörwag family ownership; professional management under CEO Jochen Schlindwein and CFO Gerhard Mayer has been in place since 2015. Corporate strategy emphasizes organic growth (10.5% organic revenue growth in 2024), bolt-on M&A targeting companies with up to €250M annual turnover, and continuous product innovation backed by a European patent estate.

Name

WÖRWAG Pharma

Legal name

Wörwag Pharma GmbH & Co. KG

Website

https://woerwagpharma.com

Company type

Private

Founded year

1971

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Wörwag Pharma is a family-owned German pharmaceutical company founded in 1971 that develops and distributes biofactor-based prescription, OTC, and dietary supplement products for diabetic comorbidities, nervous system, musculoskeletal, and immune indications through pharmacy-exclusive channels across 35+ countries.

Ownership category

akta.pro rank

Product category

Biofactor Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

akta.pro secondary industries

Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives (EUAAAIAK), Probiotics & Digestive Health Supplements (CRADAGAF), Medical Nutrition & Meal Replacement (RTD, Bars, Powders) (CRADAGAN), Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD)

Keywords

• Biofactor pharmaceuticals
• Diabetic comorbidities treatment
• OTC pharmaceutical manufacturing
• Vitamin mineral supplements
• Pharmacy distribution network

Headquarters

HQ city

Böblingen

HQ country

Germany

HQ region

Europe

Offices3 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Supply Chain, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from sale of biofactor-based pharmaceutical products (OTC and Rx) exclusively through pharmacy channels. Products include vitamins, minerals, trace elements, and herbal ingredients for therapeutic applications in diabetic comorbidities, nervous system, musculoskeletal system, and immune system support.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Wörwag Pharma develops, manufactures, and sells biofactor-based pharmaceutical products—both OTC (over-the-counter) and prescription (Rx)—focused on four therapeutic areas: diabetic comorbidities, nervous system disorders, musculoskeletal system health, and immune system support. Core product lines include the long-established Milgamma and Magnerot OTC brands, the newly launched Lagosa Triplex® nutrient combination (omega-3, choline, milk thistle with enhanced silymarin bioavailability), and ReDia® fiber-based dietary supplement for metabolic health, all sold exclusively through pharmacy channels across 35+ countries.

Product overview

Wörwag Pharma is a family-owned pharmaceutical company offering a pharmacy-exclusive product portfolio of prescription (Rx) and over-the-counter (OTC) products as well as dietary supplements. The company specializes in four therapeutic areas: diabetic comorbidities (including diabetic polyneuropathy), nervous system disorders, musculoskeletal system health, and immune system support. Core products include Milgamma and Magnerot (established OTC brands), the newly launched Lagosa Triplex® (omega-3/choline/milk thistle combination), and ReDia® (fiber-based metabolic health supplement). The company develops and produces biofactor-based medicines leveraging vitamins, minerals, trace elements, and herbal ingredients. Manufacturing is conducted at two in-house facilities: Wörwag Pharma Operations (WPO) in Poland and Wörwag Pharma Production (WPP) in Germany. Products are distributed across 35+ countries in Europe, Asia, and South America.

Differentiator

Problem solved

Functional benefit

Brands

• Milgamma: OTC regulated medicine, ranked #2 in Bulgarian market with €10.7M retail sales in 2025
• Magnerot
• Lagosa Triplex
• ReDia
• magnerot CLASSIC
• AAA-Pharma
• milgamma

Products and services

• Milgamma Over-the-counter pharmaceutical product for nervous system support using B-complex vitamins, ranked #2 among OTC regulated medicines in Bulgaria with €10.7M retail sales in 2025.
• Magnerot Over-the-counter pharmaceutical product for musculoskeletal and cardiovascular support using magnesium-based formulation, ranked #7 among OTC regulated medicines in Bulgaria with €7.7M sales and 23.2% growth in 2025.
• Lagosa Triplex® Scientifically formulated nutrient combination supporting heart, liver, and lipid metabolism, combining omega-3 fatty acids, choline, and milk thistle with 8.6x higher silymarin bioavailability, available in 60-capsule packs.
• ReDia® Fiber-based dietary supplement for metabolic health, protected by European patent EP3679924B1 across 25 European countries.
• Benfotiamine Vitamin B1 derivative developed by founder Dr. Fritz Wörwag into a therapeutic milestone for diabetic comorbidities, used as a high bioavailability active ingredient for preventing vitamin B1 deficiency.

Quantifiable outcome

• Milgamma achieved #2 OTC ranking in Bulgaria with €10.7M sales
• +3 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered core and minor.

• Biomed AGcoreChannel Partner/ Reseller/ Distributor · 1 April 2026Strategic collaboration announced May 2026 for Swiss market. Effective April 1, 2026, Biomed AG serves as the distribution partner for Wörwag Pharma products in Switzerland, expanding the company's pharmacy distribution network into the Swiss market.
• Herrnhuter MissionshilfeminorOthersCorporate Social Responsibility partnership supporting vocational schools in Africa. Wörwag Pharma supports educational initiatives in African communities through this partnership, demonstrating commitment to social responsibility beyond core business operations.

Scale indicators9 records

Recent moves12 records

Expansion highlights5 records

Broad incumbents

• Stada Arzneimittel: Large European generics and specialty pharma with extensive OTC and consumer healthcare portfolio sold through pharmacies in 30+ countries. Overlaps with Wörwag in OTC pharmacy products and European footprint but operates at much greater scale with a broader therapeutic mix.
• Almirall: European specialty pharma headquartered in Spain with a dermatology-led portfolio and broader OTC presence in European markets. Comparable as a European specialty pharma of similar profile, though with a different therapeutic emphasis.
• Recordati: European specialty pharma with a primary care and rare disease focus, listed on the Italian stock exchange. Comparable as a European mid-cap specialty pharma with diabetes and cardiovascular adjacency, though substantially larger and broader in scope.
• Merz Pharma: Privately held German specialty pharma combining Rx, OTC, and aesthetic products with international distribution. Comparable as a family-influenced German pharma with branded specialty products in multiple therapeutic areas, though larger and more diversified.

Direct peers

• Hermes Arzneimittel: German family-owned OTC and self-medication pharma with a comparable portfolio of vitamins, minerals, and consumer health products sold via pharmacy channels across Europe. Similar size, family-controlled governance, and pharmacy-exclusive distribution make Hermes a direct comparator.
• Bionorica SE: German family-owned pharma specializing in phytopharmaceutical (herbal) medicines sold primarily through pharmacies and prescribed by physicians. Strong direct comparator on botanical/pharmaceutical positioning, family ownership, and pharmacy-channel sales model.
• Cesra Arzneimittel: German family-owned pharma specializing in homeopathic and natural medicinal products distributed through pharmacies. Smaller than Wörwag but closely comparable on botanical/natural pharmaceutical positioning and German pharmacy-channel focus.
• Heel (Biologische Heilmittel Heel): German family-owned pharma producing combination biological and natural medicines sold internationally through pharmacies and healthcare practitioners. Comparable on German family ownership, biological/natural pharmaceutical positioning, and global pharmacy distribution.
• Klosterfrau München: German family-owned OTC pharma selling traditional herbal and natural health products via pharmacy and drugstore channels. Comparable on family ownership, botanical heritage, and pharmacy-driven go-to-market in German-speaking markets.
• Dermapharm Holding: German mid-cap pharma focused on branded off-patent and OTC healthcare products with strong pharmacy distribution in Germany and selected international markets. Comparable in scale, pharmacy-channel go-to-market, and branded-generic portfolio strategy.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/woerwagpharma
• Instagraminstagram.com/woerwagpharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about WÖRWAG Pharma